Magnitude and risk factors of non-communicable diseases among people living with HIV in Tanzania: a cross sectional study from Mbeya and Dar es Salaam regions

BMC Public Health

Sayoki G Mfinanga²  Godlisten S Materu³  Amos M Kahwa²  Andrew M Kilale¹  Akili K Kalinga³  Godfather D Kimaro²  Ester S Ngadaya²  Mary T Mayige³  Gibson B Kagaruki³ 

[1] University of Bergen, Centre for International Health, Bergen, Norway;National Institute for Medical Research-Muhimbili Center, Dar es Salaam, Tanzania;National Institute for Medical Research-Tukuyu Center, P.O. Box 538, Tukuyu, Mbeya, Tanzania

关键词: Tanzania;    People living with HIV;    ART;    Risk factors;    Non-communicable diseases;   

Others  :  1128079
DOI  :  10.1186/1471-2458-14-904

 received in 2013-11-07, accepted in 2014-08-29,  发布年份 2014

【 摘 要 】

Background

HIV and Non communicable diseases (NCDs) are major problem of public health importance in developing countries. This study was conducted to explore and establish information on the magnitude, distribution of NCDs risk factors among people living with HIV (PLWHIV) which is scarce in Tanzania.

Method

A cross sectional study was conducted to PLWHIV from 12 care and treatment clinics in Dar es Salaam and Mbeya regions from October 2011 to February 2012. Data on demographic characteristics, NCD risk factors including behavioral, biochemical tests and physical measurements was collected from PLWHIV.

Results

Of 754 PLWHIV recruited, 671(89.0%) consented to participate in the study and 354/671(52.8%) were on antiretroviral therapy (ART). The following NCD risk factors: raised blood levels of low density lipoprotein (61.3% vs 38.7%, p < 0.001) total cholesterol (TC) (71.6% vs 28.4%, p < 0.001) and triglyceride (67.0% vs 33.0%, p = 0.001) as well as overweight/obesity (61.1% vs 38.9%, p = 0.010), abnormal waist circumference (61.7% vs 38.3%, p < 0.001) and being aged >40 years (63.3% vs 36.7%, p < 0.001) were more prevalent among PLWHIV on ART than ART naïve. The prevalence of Diabetes mellitus among PLWHIV was 4.2% and was slightly high among those ART naïve (4.7% vs 3.7%). The prevalence of hypertension was 26.2% and was high among those on ART (30.0% vs 21.9%, p = 0.010). Being aged >40 years (AOR = 2.52, 95% CI 1.37-4.63), abnormal waist circumference (AOR = 2.37 95% CI 1.13-5.00), overweight/obesity (AOR = 2.71, 95% CI 1.26-5.84) and male sex (AOR = 1.17, 1.02-4.20) were the predictors of hypertension among patients on ART while raised TC (AOR = 1.47 (1.01-2.21) and being aged >40 years (AOR = 3.42, 95% CI 2.06-5.70) were predictors for hypertension among ART naïve patients.

Conclusion

This study has revealed that the magnitude of NCD risk factors is significantly higher among PLWHIV on ART than those not on ART. Initiating and strengthening of interventions for minimizing preventable NCD risks should be considered when initiating ART among PLWHIV. Regular monitoring of NCD risk factors is of paramount importance among ART patients.

【 授权许可】

   
2014 Kagaruki et al.; licensee BioMed Central Ltd.

【 参考文献 】

• [1]Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), National Bureau of Statistics (NBS), Office of the Chief Government Statistician (OCGS), and ICF International: Tanzania HIV/AIDS and Malaria Indicator Survey 2011–12. Dar es Salaam, Tanzania: TACAIDS, ZAC, NBS, OCGS, and ICF International; 2013.
• [2]Tanzania Commission for AIDS (TACAIDS), National Bureau of Statistics (NBS), and ORC Macro: Tanzania HIV/AIDS Indicator Survey 2003–04. Calverton, Maryland, USA: TACAIDS, NBS, and ORC Macro; 2005.
• [3]Tanzania Commission for AIDS (TACAIDS), Zanzibar AIDS Commission (ZAC), National Bureau of Statistics (NBS), Office of the Chief Government Statistician (OCGS), and Macro International Inc: Tanzania HIV/AIDS and Malaria Indicator Survey 2007–08. Dar es Salaam, Tanzania: TACAIDS, ZAC, NBS, OCGS, and Macro International Inc; 2008.
• [4]URT: National Multisectoral HIV Prevention Strategy 2009–2012 ‘Towards achieving Tanzania without HIV. 2009.
• [5]Rabkin M, Nishtar S: Scaling up chronic care systems: Leveraging HIV programs to support noncommunicable diseases services. J Acquir Immune Defic Syndr 2011, 57(Suppl2):S87-S90.
• [6]Hirschhorn LR, Kaaya SF, Garrity PS, Chopyak E, Fawzi MCS: Cancer and the 'other' noncommunicable chronic diseases in older people living with HIV/AIDS in resource‒limited settings: A challenge to success. AIDS 2012, 26(SUPPL.1):S65-S75.
• [7]Nigatu T: Integration of HIV and Noncommunicable Diseases in Health Care Delivery in Low- and Middle-Income Countries. Prev Chronic Dis 2012, 9:110331.
• [8]Eliseo A, Morgello ES, Klotman ME, Mosoian A, Lento PA, Berman JW, Schecter AD: Human Immunodeficiency Virus (HIV) Infects Human Arterial Smooth Muscle Cells in Vivo and in Vitro: Implications for the Pathogenesis of HIV-Mediated Vascular Disease. Am J Pathol 2008, 172(4):1100-1111.
• [9]Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, Waters DD: Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004, 109:316-319.
• [10]de Saint Martin L, Vandhuick O, Guillo P, Bellein V, Bressollette L, Roudaut N, Amaral A, Pasquier E: Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 2006, 185:361-367.
• [11]Segev A, Cantor WJ, Strauss BH: Outcome of percutaneous coronary intervention in HIV-infected patients. Catheter Cardiovasc Interv 2006, 68:879-881.
• [12]Andrew C, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12(7):F51-F58.
• [13]Kotler DP: HIV and antiretroviral therapy: lipid abnormalities and associated cardiovascular risk in HIV-infected patients. J Acquir Immune Defic Syndr 2008, 49(Suppl. 2):S79-S85.
• [14]Currier J, Scherzer R, Bacchetti P, Heymsfield S, Lee D, Sidney S, Tien PC: Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. J Acquir Immune Defic Syndr 2008, 48(1):35-43.
• [15]Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett AR: Changes in serum lipids among HIV-infected men on highly active antiretroviral therapy. HIV Med 2007, 8(5):280-287.
• [16]Crane HM, Grunfeld C, Willig JH, Mugavero MJ, Van Rompaey S, Moore R, Rodriguez B, Feldman BJ, Lederman MM, Saag MS, Kitahata MM: Impact of NRTIs on lipid levels among a large HIV-infected cohort initiating antiretroviral therapy in clinical care. AIDS 2011, 25(2):185-195.
• [17]Michael DP, Stein JH, Aberg JA, Fichtenbaum CJ, Gerber JG, Tashima KT, Henry WK, Currier JS, Sprecher D, Glesby MJ: Guidelines for the Evaluation and Management of Dyslipidemia in Human Immunodeficiency Virus (HIV)–Infected Adults Receiving Antiretroviral Therapy: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003, 37(5):613-627.
• [18]Dau BT, Holodniy M: The Relationship between HIV Infection and Cardiovascular Disease: Current Cardiology Reviews. Academic Journal 2008, 4(3):203-218.
• [19]Savès M, Raffi F, Capeau J, Rozenbaum W, Ragnaud JM, Perronne C, Basdevant A, Leport C, Chêne G: Factors related to lipodystrophy and metabolic alterations in patients with human immunodeficiency virus infection receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002, 34(10):1396-1405.
• [20]Hejazi N, Lee MHS, Geok Lin K, Lee C, Choong K: Factors Associated with Abdominal Obesity among HIV-infected Adults on Antiretroviral Therapy in Malaysia. Global Journal of Health Science 2010, 2(20):20-31.
• [21]Crum CN, Tejidor R, Medina S, Barahona I, Ganesan A: Obesity among Patients with HIV. The Latest Epidemic AIDS Patient Care and STDs 2008, 22(12):925-930.
• [22]Denue BA, Muazu PJ, Gashau W, MBO DN, Ajayi NA: Effects of highly active antiretroviral therapy (HAART) on blood pressure changes and its associated factors in HAART naive HIV-infected patients in north eastern Nigeria. Archives of Applied Science Research 2012, 4(3):1447-1452.
• [23]Dusara P, Bussmann H, Lima C, Tsalaile L, Makhema J, Campa A, Widenfelt E, Sales S, Li Y, Burns PJ, Marlink R, Baum MK: Predictors of hypertension among HIV infected adults in Botswana, Africa [J]. Faseb J 2009, 23:551.20. (Meeting abstrac)
• [24]Brown TT, Cole SR, Li X, Kingsley LA, Palella FJ, Riddler SA, Visscher BR, Margolick JB, Dobs AS: Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med 2005, 165(10):1179-1184.
• [25]Kumwenda J, Mateyu G, Kampondeni S, Van Dam P, Lvan L, Zijlstra E: Differential diagnosis od stroke in a setting of high HIV prevalence in Blantyre Malawi. Malawi Med J 2005, 17(4):107-111.
• [26]Mlayi M, Bakari M: The prevalence of HIV among patients admitted with stroke at the Muhimbili National Hospital, Dar es Salaam, Tanzania. Tanzan J Health Res 2010, 12(2):1-12.
• [27]Schwartz EJ, Szczech LA, Ross MJ, Klotman ME, Winston JA, Klotman PE: Highly active antiretroviral therapy & the epidemic of HIV + end-stage renal disease. J Am Soc Nephrol 2005, 16(8):2412-2420.
• [28]Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R: Swiss HIV Cohort Study: Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study. Clin Infect Dis 2007, 45(1):111-119.
• [29]Bloomfield G, Hogan J, Keter A, Sang E, Carter J, Velasquez E, Kimaiyo S: Hypertension and obesity among as cardiovascular risk factors among HIV seropositive patients in western Kenya. PLoS ONE 2011, 6(7):e22288.
• [30]Somi G, Matee M, Makene CL, van den Hombergh J, Kilama B, Yahya-Malima KI, Masako P, Sando D, Ndayongeje J, Rabiel B, Swai RO: Three years of HIV/AIDS care and treatment services in Tanzania: achievements and challenges. Tanzan J Health Res 2009, 11(3):136-143.
• [31]Kothari CR: Research Methodology, Methods and Techniques (Second Revised Edition). New Delhi India: New Age International Publishers; 2004.
• [32]WHO: Prevention of Cardiovascular Disease Pocket Guidelines for Assessment and Management of Cardiovascular Risk. Geneva:; 2007.
• [33]WHO: Non-Communicable Diseases in the South Asia Region. WHO Regional Office for South East Asia New Delhi; 2002. SEA/NCD/54
• [34]WHO: Physical Status: The Use and Interpretation of Anthropometry. Report of a WHO Expert Committee WHO Technical Report Series 854. Geneva: World Health Organization; 1995.
• [35]WHO: WHO STEPwise Approach to Surveillance (STEPS). Geneva: World Health Organization (WHO); 2008a.
• [36]WHO: Waist Circumference and Waist–Hip Ratio: Report of a WHO Expert Consultation Geneva. 2008b.
• [37]IDF: The IDF Consensus Worldwide definition of the Metabolic Syndrome. International Diabetes Federation (IDF); 2006.
• [38]WHO: Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Geneva: World Health Organisation; 1999.
• [39]Omech B, Sempa J, Castelnuovo B, Opio K, Otim M, Mayanja-Kizza H, Colebunders R, Manabe YC: Prevalence of HIV-Associated Metabolic Abnormalities among Patients Taking First-Line Antiretroviral Therapy in Uganda. ISRN AIDS 01/2012; 2012:960178. doi:10.5402/2012/960178
• [40]Hurley E, Coutsoudis A, Giddy J, Knight SE, Loots E, Esterhuizen TM: Weight evolution and perceptions of adults living with HIV following initiation of antiretroviral therapy in a South African urban setting. S Afr Med J 2011, 101:645-650.
• [41]Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E, Komarow L: Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PLoS One 2009, 4(5):e5575.
• [42]Mwangemi F, Lamptey P: Integration of HIV and CVD Services in Kenya [Oral Presentation]. Vienna, Austria: HIV and Health Systems Pre-conference; 2010.
• [43]UNAIDS report: Chronic Care of HIV and Non Communicable Diseases; How to Leverage the HIV Experience?. 2011, 1-16.
• [44]Hejazi N, Huang MS, Lin KG, Choong LC: Hypertension among HIV-infected adults receiving highly active antiretroviral therapy (HAART) in Malaysia. Glob J Health Sci 2013, 6(2):58-71.
• [45]Puttawong S, Prasithsirikul W, Vadcharavivad S: Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thail 2004, 87(6):605-611.
• [46]Zannou DM, Denoeud L, Lacombe K, Amoussou Guenou D, Bashi J, Akakpo J, Girard PM: Incidence of lipodystrophy and metabolic disorders in patients starting nonnucleoside reverse transcriptase inhibitors in Benin. International Medical Press 2009, 14(3):371-380.
• [47]At Work Issue: A Quarterly Publication of the Institute for Work & Health Issue 55 Winter. 2009. http://www.iwh.on.ca/system/files/at-work/at_work_55.pdf: webcite downloaded on 11th September 2013
• [48]Skovdal M, Campbell C, Madanhire C, Mupambireyi Z, Nyamukapa C, Gregson S: Masculinity as a barrier to men's use of HIV services in Zimbabwe. Global Health 2011., 7(13)
• [49]Herstad B: Addressing Gender Issues Related to HIV Treatment Adherence Programs. Washington, DC: Futures Group, the USAID Health Policy Initiative, Task Order 1; 2010.